Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 22, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
November 16, 2021 16:30 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to...
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results
November 11, 2021 16:01 ET
|
Atea Pharmaceuticals, Inc.
Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data...
Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021
November 04, 2021 07:53 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
For the 12th Time, Access Recognized on the Inc. 5000, With Three-Year Revenue Growth of 43 Percent
November 03, 2021 12:15 ET
|
Access
WOBURN, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Access, the world’s largest privately-held integrated information management services provider, today announced that it is being recognized for the...
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
October 19, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms In high-risk...
Atea Pharmaceuticals to Present Virology and Early Clinical Data at the ISIRV-WHO Virtual Conference 2021
October 07, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will present analyses confirming...
Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference
September 29, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
DKBinnovative Named to the Prestigious Inc. 5000 List for the 5th Consecutive Year
September 09, 2021 05:00 ET
|
DKBinnovative
FRISCO, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Inc. magazine has ranked DKBinnovative as No. 2,397 on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing...
Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 07, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...